Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amylyx Pharmaceuticals, Inc. - Common Stock (NQ: AMLX )

3.715 +0.045 (+1.23%)
Streaming Delayed Price Updated: 11:54 AM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amylyx Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
FDA Sets Up Adcomm To Review Amylyx's ALS Drug Next Month
The FDA's Peripheral and Central Nervous System Drugs Advisory Committee will review Amylyx Pharmaceuticals Inc's (NASDAQ: AMLX) marketing application for... 
Via Benzinga
The Daily Biotech Pulse: J&J Unit Announces Research Collaboration With Remix, Regencell Touts COVID Data, Decision Day For Agios
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Amylyx's ALS Treatment Regulatory Application To Be Reviewed By FDA Panel... 
Via Benzinga
Amylyx Pharmaceuticals Announces FDA Advisory Committee Meeting to Review New Drug Application for AMX0035 for the Treatment of ALS Scheduled for March 30, 2022
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals to Present at the 11th Annual SVB Leerink Global Healthcare Conference
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
47 Biggest Movers From Yesterday
Gainers Nuvectis Pharma, Inc. (NASDAQ: NVCT) shares surged 144.6% to close at $7.95 on Monday. The company, on Friday, priced its IPO at $5 per share. Anghami Inc. (NASDAQ: ANGH... 
Via Benzinga
The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News
The broader market weakness pervaded into the biotech sector in the week ending Jan. 28, sending stocks lower. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 2, 2022
Upgrades Oppenheimer upgraded the previous rating for NovoCure Ltd (NASDAQ:NVCR) from Perform to Outperform. NovoCure earned $0.13 in the third quarter, compared to $0.09... 
Via Benzinga
Opening Day: Credo Rises In First Trading Day Despite Tough IPO Market
Shares of Credo Technology rose more than 12% in their first trading day despite a tough IPO market. This was the first big technology offering of the year after Justworks postponed its deal that had... 
Via Talk Markets
48 Biggest Movers From Yesterday
Gainers Splash Beverage Group, Inc. (NYSE: SBEV) shares jumped 70.6% to close at $1.80 on Tuesday after the company announced it received authorization to sell its TapouT... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Jaguar Health (NASDAQ:JAGX) stock... 
Via Benzinga
Barron's Latest Picks And Pans: Visa, AT&T, Biogen, Robinhood And More
This weekend's Barron's cover story says commodities may not be as exciting as crypto or tech stocks, but they could be the right investment at the right time. Other... 
Via Benzinga
The Daily Biotech Pulse: Glaukos Gets FDA Nod, Neurocrine Preannounces Soft Ingrezza Sales, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hepion's Lead NASH Drug Candidate Gets The Non-Proprietary Name... 
Via Benzinga
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.